InflaRx N.V. (IFRX) stock
IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.17−0.07 (-5.65%)
Close on Nov 13, 2026Market cap $84.58MP/E –Yield –
InflaRx r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €25.72M, down 27.3% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is €44.58M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €25.72M | -27.3% |
| FY2024 | Dec 31, 2024 | €35.36M | -13.8% |
| FY2023 | Dec 31, 2023 | €41.02M | +9.3% |
| FY2022 | Dec 31, 2022 | €37.53M | +5.1% |
| FY2021 | Dec 31, 2021 | €35.70M | +39.0% |
| FY2020 | Dec 31, 2020 | €25.68M | -42.4% |
| FY2019 | Dec 31, 2019 | €44.58M | +78.1% |
| FY2018 | Dec 31, 2018 | €25.03M | +73.6% |
| FY2017 | Dec 31, 2017 | €14.41M | +173.1% |
| FY2016 | Dec 31, 2016 | €5.28M | +51.8% |
| FY2015 | Dec 31, 2015 | €3.48M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | €7.20M | -36.3% |
| Q2 FY2024 | Jun 30, 2024 | €10.02M | -19.8% |
| Q2 FY2023 | Jun 30, 2023 | €10.92M | +117.0% |
| Q2 FY2022 | Jun 30, 2022 | €11.18M | – |
| Q2 FY2021 | Jun 30, 2021 | €11.30M | – |
| Q2 FY2019 | Jun 30, 2019 | €12.50M | – |
| Q2 FY2018 | Jun 30, 2018 | €5.03M | – |
See a number that looks wrong?